GlassScriptPhysician profile
Anusha Imran
NPI 1932867462
$4,547.88
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,370 · 2023: $1,784 · 2024: $1,394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,177.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $651.36 | 2022-2024 | Rystiggo, Zilbrysq, Briviact |
| Abbvie INC. | $564.92 | 2022-2024 | |
| Amgen INC. | $280.27 | 2022-2023 | Otezla, Aimovig |
| Biogen, INC. | $277.30 | 2022-2023 | Vumerity, Tysabri, Skyclarys |
| Alexion Pharmaceuticals, INC. | $250.20 | 2022-2024 | Ultomiris, Soliris |
| Pfizer INC. | $231.47 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $206.00 | 2022-2024 | |
| Lundbeck LLC | $190.39 | 2022-2024 | Vyepti |
| Emd Serono, INC. | $144.52 | 2022-2024 | Mavenclad |
| Lilly USA, LLC | $129.86 | 2022-2023 | Amyvid, Emgality, Reyvow |
| Genentech USA, INC. | $121.24 | 2022-2024 | Ocrevus |
| Argenx US, INC. | $116.93 | 2022-2024 | Vyvgart |
| Genzyme Corporation | $114.49 | 2022-2023 | |
| Grifols USA, LLC | $100.79 | 2022-2024 | Gamunex-C |
| Sk Life Science, INC. | $90.21 | 2023 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anusha Imran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.